Early Pregnancy Loss Clinical Trial
Official title:
Cell-free DNA Analysis of Chromosome Anomalies in Early Pregnancy Loss
NCT number | NCT04935138 |
Other study ID # | CD20-011 |
Secondary ID | |
Status | Terminated |
Phase | |
First received | |
Last updated | |
Start date | June 1, 2021 |
Est. completion date | December 31, 2022 |
Verified date | November 2023 |
Source | Quest Diagnostics-Nichols Insitute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The study assesses the accuracy of cell-free DNA (cfDNA) analysis in detecting whole chromosomal aneuploidies from maternal plasma of patients with early, missed miscarriage.
Status | Terminated |
Enrollment | 78 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | |
Gender | Female |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - 5-20 weeks of gestation by ultrasound - Miscarriage diagnosed by ultrasound - Pregnancy tissue still present in utero, including an empty sac, and not completely expelled Exclusion Criteria: - Maternal age < 18 years - No visible pregnancy tissue on ultrasound - Multiple fetal gestation (> than singleton) - Pregnancy was conceived using in vitro fertilization (IVF) with preimplantation genetic testing for aneuploidy (PGT-A) performed on the transferred embryo - No microarray testing is planned on the product of conception - Previous normal non-invasive prenatal testing (NIPT) or diagnostic testing (chorionic villous sampling or amniocentesis) in the current pregnancy - Patient unable to provide consent |
Country | Name | City | State |
---|---|---|---|
United States | Quest Diagnostics | San Juan Capistrano | California |
Lead Sponsor | Collaborator |
---|---|
Quest Diagnostics-Nichols Insitute | Illumina, Inc. |
United States,
Barisic I, Zergollern L, Muzinic D, Hitrec V. Risk estimates for balanced reciprocal translocation carriers--prenatal diagnosis experience. Clin Genet. 1996 Mar;49(3):145-51. doi: 10.1111/j.1399-0004.1996.tb03274.x. — View Citation
ESHRE. European Society of Human Reproduction and Embryology guideline: recurrent pregnancy loss. Human Reproduction Open 2018: 1-12.
Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril. 2012 Nov;98(5):1103-11. doi: 10.1016/j.fertnstert.2012.06.048. Epub 2012 Jul 24. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | microarray analysis of products of conception (POC) | chromosome anomalies | 7 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04595760 -
Factors Influencing Fertility or Pregnancy Health
|
||
Completed |
NCT01132924 -
A Follow-up of the Early Pregnancy Study Cohort.
|
||
Recruiting |
NCT05880381 -
Virtual Reality for Coping With Involuntary Early Pregnancy Loss
|
N/A | |
Completed |
NCT04410029 -
Evaluation of a Decision Aid for Early Pregnancy Loss
|
N/A | |
Not yet recruiting |
NCT06452719 -
Letrozole and Misoprostol for Early Pregnancy Loss Management: A Prospective Pilot Cohort Study
|
Phase 2 | |
Recruiting |
NCT04738370 -
Assessment of Biomarkers in Pregnancy on Unknown Location and Ectopic Pregnancy
|
||
Not yet recruiting |
NCT06309927 -
Operative Hysteroscopy Versus Suction Curettage for Surgical Termination of Early Pregnancy Loss (Miscarriage)
|
N/A |